A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
University of California, Irvine
Astellas Pharma Inc
Janssen Research & Development, LLC
Kyowa Kirin Co., Ltd.
Oscotec Inc.
Fate Therapeutics
IDEAYA Biosciences
BioNTech SE
M.D. Anderson Cancer Center
University of Chicago
Memorial Sloan Kettering Cancer Center
Memgen, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Shanghai Jiao Tong University School of Medicine